Laura J. Hamill has deep experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. Most recently, she served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc., where she was accountable for 2,200 employees and $22 billion in annual revenue and led the global commercial strategic direction and long-term planning. Over an 18-year career at Amgen, Ms. Hamill held several executive roles in the United States and internationally. In her last role as Senior Vice President and General Manager of US Commercial Operations, she managed 2,000 employees across all of Amgen’s therapeutic areas with annual revenue of $20 billion. She also served as the Chairperson of Amgen’s Senior Women’s Leadership Council, member of the Amgen Foundation and other key corporate governance committees. Ms. Hamill is currently a member of the board of directors for Pardes Biosciences, BB Biotech and Y-mAbs Therapeutics. She also is a board member for a private company, Unchained. Ms. Hamill holds a bachelor’s degree in business administration from the University of Arizona.